Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma-Reference-Cited by-同舟云学术

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma

Published:2016-12-29 Issue:4 Volume:66 Page:475-489
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Chen Cheng,Li Kesang,Jiang Hua,Song Fei,Gao Huiping,Pan Xiaorong,Shi Bizhi,Bi Yanyu,Wang Huamao,Wang Hongyang,Li Zonghai

Funder

the National Natural Science Foundation of China

the 13th Five-Year Plan for Science and Technology Research of China

One Hundred Talents Scientific Research Projects of Health System in Shanghai

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1949-8.pdf

Reference44 articles.

1. Li ZH, Chen C, Li KS, Jiang H, Song F, Gao HP, Pan XR, Shi BZ, Bi YY, Wang HM, Wang HY (2016) Development of T-cells carrying two complementary chimeric antigen receptors against GPC3 and ASGR1 for the treatment of hepatocellular carcinoma. Mol Ther 24(supplement 1):S79. doi: 10.1038/mt.2016.78

2. Cancer IAfRo (2014) World cancer report 2014. WHO, Geneva

3. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J, Barcelona Liver Cancer G (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739. doi: 10.1016/S0140-6736(02)08649-X

4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. doi: 10.1056/NEJMoa0708857

5. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106–6115. doi: 10.1158/1078-0432.CCR-06-1183

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder;Experimental Hematology & Oncology;2024-08-19

2. Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies;Frontiers in Bioscience-Landmark;2024-07-24

3. Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer;Clinical Cancer Research;2024-05-15

4. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives;Journal of Hematology & Oncology;2024-04-29

5. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances;Journal of Controlled Release;2024-04